Mayo Clinic Cardiovascular Disease Biobank

Overview

About this study

The purpose of this study is to determine the innate immune, cell death and oxidative stress changes in the myocardium, and aorta of patients with heart failure compared to patients with normal hearts.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 18 years of age and older.
  • Patients undergoing left ventricular assist device implantation, heart transplantation, and donor hearts.

Exclusion Criteria: 

  • Patients with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/15/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul Tang, M.D., Ph.D.

Open for enrollment

Contact information:

Paul Tang M.D., Ph.D.

(507) 255-9505

Tang.Paul2@mayo.edu

More information

Publications

Publications are currently not available